Latest News

Activists say a patent office lawyer’s tweets showed ‘bias’ in favor of Gilead in HIV drug case

One day after AIDS activists petitioned the U.S. Patent and Trademark Office last week to reject a request by Gilead Sciences (GILD) for a patent extension on an HIV drug, a senior legal adviser at the federal agency tweeted contentious remarks about their right to take such a step. She also challenged a key point in their filing.

Now, the activists have filed yet another petition with the USPTO and accused the legal adviser of making inappropriate remarks and displaying favoritism toward Gilead. And the activists, known as the PrEP4All Collaboration, have also asked the USPTO to reassign the adviser — a 14-year-employee named Mary Till — while their petition remains active.

Read the rest…

Source link




Related posts

Rapid COVID-19 Clinical Practice Guidelines (2020)

Newsemia

Red wine could benefit gut bacteria finds study

Newsemia

Promedica International et Dr. Agarwal’s Eye Hospitals établissent une alliance stratégique

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy